159 related articles for article (PubMed ID: 19751237)
1. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
Br J Haematol; 2009 Dec; 147(5):677-80. PubMed ID: 19751237
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).
Gertz MA; Rue M; Blood E; Kaminer LS; Vesole DH; Greipp PR
Leuk Lymphoma; 2004 Oct; 45(10):2047-55. PubMed ID: 15370249
[TBL] [Abstract][Full Text] [Related]
3. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
[TBL] [Abstract][Full Text] [Related]
4. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
7. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
Treon SP; Hanzis C; Manning RJ; Ioakimidis L; Patterson CJ; Hunter ZR; Sheehy P; Turnbull B
Br J Haematol; 2011 Aug; 154(3):357-62. PubMed ID: 21615385
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
14. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
[TBL] [Abstract][Full Text] [Related]
15. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
[TBL] [Abstract][Full Text] [Related]
16. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
17. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
18. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14.
Mori A; Tamaru J; Kondo H
Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
